Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(−)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis

To investigate the incidence and risk factors of hepatitis B virus (HBV) reactivation in HBV surface antigen (HBsAg)(−)/ HBV core antibody (HBcAb)(+) patients who underwent rituximab (RTX) therapy for rheumatoid arthritis (RA). From January 2000 through December 2017, a total of 134 RA patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Meng Hsuan, Tseng, Chih-Wei, Lee, Chi-Hui, Tung, Chien-Hsueh, Tseng, Kuo-Chih, Lai, Ning-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016116/
https://www.ncbi.nlm.nih.gov/pubmed/32051458
http://dx.doi.org/10.1038/s41598-020-59406-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016116/
https://www.ncbi.nlm.nih.gov/pubmed/32051458
http://dx.doi.org/10.1038/s41598-020-59406-4

Ejemplares similares